Abstract
We have studied a knockout mouse with fumarylacetoacetate hydrolase (FAH) deficiency as a model of human hereditary tyrosinaemia type I (HT1). These mice have a phenotype very similar to the human disease, which is characterized by acute hepatic failure, renal tubular disease and hepatocarcinoma. We have previously reported on the efficacy of 2-(2-nitro-4-trifluoromethylbenzyol)-1,3-cyclohexanedione (NTBC) in preventing acute liver disease in HT1 mice. Here we present a progress report on long-term follow up (>1 year) of high-dose NTBC therapy in combination with tyrosine restriction. In vivo retroviral gene therapy was also effective in abolishing the acute liver failure of HT1. Retrovirally treated mice remained completely healthy and active for 12 months after retroviral gene transfer. However, hepatocarcinoma developed in 2/3 treated animals after 1 year. Southern blot analysis showed that the tumours did not arise from retrovirally transduced hepatocytes but from non-corrected FAH-deficient cells. These results highlight the extreme danger for tumour formation in HT1 and indicate the need for improved gene therapy that leads to the elimination of endogenous FAH-deficient liver cells.
Similar content being viewed by others
REFERENCES
Agsteribbe E, van Faassen H, Hartog MV, et al (1990) Nucleotide sequence of cDNA encoding human fumarylacetoacetase. Nucleic Acids Res 18: 1887.
Bain MD, Purkiss P, Jones M, Bingham P, Stacey TE, Chalmers RA (1990) Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinemia type I. Eur J Pediatr 149: 637–639.
Bird S, Miller NJ, Collins JE, Rice-Evans CA (1995) Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC. J Inher Metab Dis 18: 123–126.
Demers SI, Tanguay RM (1991a) BqlII RFLP for the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 1965.
Demers SI, Tanguay RM (1991b) MspI RFLP in the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 6971.
Demers SI, Phaneuf D, Tanguay RM (1991) Taq1 RFLP for the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 1352.
Esquivel CO, Mieles L, Marino IR, et al (1989) Liver transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma. Transplant Proc 21: 2445–2446.
Gabrielli O, Maiorana A, Paris D, et al (1978) Presentation of a case of chronic type 1 tyrosinemia. Diet therapy and clinical outcome. Minerva Pediatr 30: 1329–1334.
Gentz J, Lindblad B, Lindstedt S, Levy L, Shasteen W, Zetterstrom R (1967). Dietary treatment in tyrosinemia (tyrosinosis). With a note on the possible recognition of the carrier state. Am J Dis Child 113: 31–37.
Giardini O, Cantani A, Kennaway NG, DÏ Eufemia P (1983) Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement. Pediatr Res 27: 25.
Gluecksohn-Waelsch S (1979) Genetic control of morphogenetic and biochemical differentiation: lethal albino deletions in the mouse. Cell 16: 225–237.
Grenier A, Lescault A (1985) Succinylacetone. In Bergmeyer HU, ed. Methods of Enzymatic Analysis. Weinheim: VCH, 79.
Grompe M, Al-Dhalimy M (1993) Mutations of the fumaryl acetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat 2: 85–93.
Grompe M, Al-Dhalimy M, Finegold M, et al (1993) Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7: 2298–2307.
Grompe M, St-Louis M, Demers SI, Al-Dhalimy M, Leclerc B, Tanguay RM (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 331: 353–357.
Grompe M, Lindstedt S, Al-Dhalimy M, et al (1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genetics 10: 453–460.
Hirakawa DA, Olson LM, Baker DH (1984) Comparative utilization of a crystalline amino acid diet and a methionine fortified casein diet by young rats and mice. Nutr Res 4: 891–895.
Holme E, Lindstedt S. (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-tri-fluoromethylbenzoyl)-1,3-cyclohexanedione). J Inter Metab Dis 21: 507–511.
Jehan P, Buchman M, Odievre M (1984) Dietary management of hereditary tyrosinemia. Apropos of 7 cases. Ann Pediatr (Paris) 31: 33–40.
Jimenez-Acosta F (1994) Painful plantar callouses and mental retardation. Tyrosinemia type II. Arch Dermatol 130: 507–511.
Kelsey G, Schütz G (1993) Lessons from lethal albino mice. Curr Opin Gen Dev 3: 259–264.
Klebig ML, Russell LB, Rinchik EM (1992) Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus. Proc Natl Acad Sci USA 89: 1363–1367.
Kvittingen EA, Jellum E, Stokke O, et al (1986) Liver transplantation in a 23-year-old tyro-sinaemia patient: effects on the renal tubular dysfunction. J Inher Metab Dis 9: 216–224.
Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R (1993) Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 91: 1816–1821.
Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P (1994) Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 94: 1657–1661.
Labelle Y, Phaneuf D, Leclerc B, Tanguay RM (1993a) Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet 2: 941–946.
Labelle Y, Puymirat J, Tanguay RM (1993b) Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. Biochim Biophys Acta 1180: 250–256.
Lindblad B, Lindstedt S, Steen G (1977) On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74: 4641–4645.
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340: 813–817.
Markowitz D, Goff S, Bank A (1988a) Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400–406.
Markowitz D, Goff S, Bank A (1988b) A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62: 1120–1124.
McLachlin JR, Mittereder N, Daucher MB, Kadan M, Eglitis MA (1993) Factors affecting retroviral vector function and structural integrity. Virology 195: 1–5.
Michals K, Matolon R, Wong PW (1978) Dietary treatment of tyrosinemia type I: importance of methionine restriction. J Am Diet Assoc 73: 507–514.
Mieles LA, Esquivel CO, Van Thiel DH, et al (1990) Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 35: 153–157.
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
Mitchell GA, Lambert M, Tanguay RM (1995) Hypertyrosinemia. In Scriver CR, Beaudet AL, Sly W, Valle D, eds. T he Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: MacGraw-Hill, 1077–1106.
Overturf K, Al-Dhalimy M, Tanguay R, et al (1996) Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nature Genetics 12: 266–273.
Overturf K, Al-Dhalimy M, Ou CN, et al (1997) Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene T her 8: 513–521.
Pérez-Cerdà C, Merinero B, Sanz P, et al (1995) Liver transplantation in nine Spanish patients with tyrosinaemia type I. J Inher Metab Dis 18: 119–122.
Paradis K, Weber A, Seidman EG, et al (1990) Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 47: 338–342.
Phaneuf D, Labelle Y, Bérubé D, et al (1991) Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet 48: 525–535.
Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM (1992) Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 90: 1185–1192.
Pronicka E, Rowinska E, Bentkowski Z, Zawadzki J, Holme E, Lindstedt S (1996) Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC). J Inher Metab Dis 19: 234–238.
Riudor E, Ribes A, Lloret J, et al (1991) Liver transplantation in two children with tyrosinaemia type I: biochemical aspects. J Inher Metab Dis 14: 281–284.
Rootwelt H, Kvittingen EA, Hoie K, et al (1992) The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency. Hum Genet 89: 229–233.
Rootwelt H, Chou J, Gahl WA, et al (1994) Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase. Hum Genet 93: 615–619.
Ruppert S, Kelsey G, Schedl A, Schmid E, Thies E, Schütz G (1992) Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev 6: 1430–1443.
Salt A, Barnes ND, Rolles K, Calne RY, Clayton PT, Leonard JV (1992) Liver transplantation in tyrosinaemia type 1: the dilemma of timing the operation. Acta Paediatr 81: 449–452.
Sambrook J, Fritsch EF, Maniatis T (eds) (1989) Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
Sokal EM, Bustos R, Van HF, Otte JB (1992) Liver transplantation for hereditary tyrosinemiäearly transplantation following the patient's stabilization. Transplantation 54: 937–939.
St-Louis M, Leclerc B, Laine J, Salo MK, Holmberg C, Tanguay RM (1994) Identification of a stop mutation in five Finnish patients su.ering from hereditary tyrosinemia type I. Hum Mol Genet 3: 69–72.
Suzuki Y, Konda M, Imai I, Imamura H, Shimao S, Okaka T (1987) Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia. Int J Pediatr Nephrol 8: 171–176.
Tada K, Wada Y, Yazaki N, Yokoyama T, Nakagawa H (1968) Dietary treatment of infantile tyrosinemia. T ohoku J Exp Med 95: 337–344.
Tanguay RM, Valet JP, Lescaul t A, et al (1990) Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 47: 308–316.
Timmers C, Grompe M (1996) Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. Hum Mutat 7: 367–369.
van-Spronsen FJ, Smit GP, Wijburg FA, Thomasse Y, Visser G, Heymans HS (1995) Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inher Metab Dis 18: 111–114.
Vrancken Peeters MJ, Lieber A, Perkins J, Kay MA (1996) Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 20: 278–285.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grompe, M., Overturf, K., Al-Dhalimy, M. et al. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report. J Inherit Metab Dis 21, 518–531 (1998). https://doi.org/10.1023/A:1005462804271
Issue Date:
DOI: https://doi.org/10.1023/A:1005462804271